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Reply to the Editor:
My colleagues and I thank Dr Katz for his
letter. Please find below our responses to
his questions.
First, regarding the morphine-sparing
effect, we believe that this not only is sta-
tistically significant but clinically meaning-
ful for these patients. As you may be
aware, patients undergoing coronary artery
bypass grafting have impaired pulmonary
function, with most having a protracted
smoking history and an increasing number
having ventricular dysfunction. Contribut-
ing as well are the effects of narcotics,
particularly when administered early (12
hours)—that is, at about the time of tra-
cheal extubation. Thus we believe that
morphine-sparring provided by the cyclo-
oxygenase 2 inhibitors parecoxib and
valdecoxib is clinically relevant and should
not just be evaluated with patient comfort
indices, as one might for less severe sur-
gery in healthier patients.
Second, we also believe that the avoid-
ance of morphine-associated physiologic
effects is more important here than possible
effects on nausea, vomiting, dizziness, se-
dation, fatigue, and constipation. Please
note that in our patients these patient com-
fort measures are affected not only by the
pain reliever administered, but also—and
more profoundly—by the effects of ex-
treme reperfusion, hypothermia, and the in-
herent cytotoxic responses affecting the
end-organs with which you have concern:
the brain (sedation, dizziness), the gut
(nausea, vomiting), and the skeletal mus-
cles and metabolism (fatigue). Generally,
then, any analyses, as I believe you sug-
gest, will be heavily confounded by these
factors in these patients.
Third, I respectfully disagree with your
comments regarding “interpretable pain
data.” We believe that reporting peak pain
intensity difference, calculated for each
day of treatment and with a baseline con-
trol, and our measures of patient and phy-
sician global assessment, are sensitive
measures, are interpretable, and are mean-
ingful. For example, regarding the clinical
relevance of a 1-unit finding on a 4-unit
pain intensity scale, we believe that this is
substantive, especially when considering
that the control group was designed to be
aggressively treated well in excess of that
usually practiced. This design was specifi-
cally chosen to be conservative, therefore
imposing a higher standard for these new
pain relievers.
Finally, and importantly, regarding
safety, we too believe that our findings
regarding infection and inflammation raise
serious concerns. We, however, believe
that analysis of historical data of similar
populations as the placebo group may re-
veal important insights. We are assured (by
the sponsor) that such analyses will be pur-
sued in the near future, and we are com-
mitted to performing those analyses inde-
pendently. Therefore, I reserve response to
this important question which you raised
until we have performed such analyses.
Those results will be given in a second
response letter to this Journal, and my
group will await your comments after that
publication.
Dennis T. Mangano, PhD, MD
Ischemia Research and Education Foundation
San Francisco, CA 94121
doi:10.1016/j.jtcvs.2003.08.039
Heterotopic right heart
transplantation
To the Editor:
In a recent issue of the Journal, Elefteri-
ades and coworkers1 published their inter-
esting short-term experimental study with
the technique for isolated accessory right
heart transplantation. The idea is definitely
clever, and this technique will open new
potential approaches in the management of
patients with congenital heart defects.
According to the suggestions of the au-
thors, this technique should be taken into
consideration as a potential alternative
treatment in two groups of patients1: (1)
children with congenital heart defects and
right heart malformation not allowing a
biventricular type of repair because of the
presence of a right ventricle that is either
underdeveloped or malfunctioning and (2)
patients with congenital heart defects and
either right ventricular failure after biven-
tricular repair in the presence of elevated
pulmonary vascular resistance, or failure of
Fontan type of procedure because of the
presence of mild to moderate increase of
pulmonary vascular resistance.
Despite the authors’ acknowledgement
that cardiac surgeons will have to consider
this new technique as simply another tool
in their armamentarium to face complex
situations, it probably is worthwhile to con-
sider other options not discussed in this
article. For the patients of group 1, the
alternative of one-and-a-half ventricular re-
pair should be always ruled out before con-
sidering accessory right heart transplanta-
tion. In most children with complex
congenital heart defects, it is possible to
use a hypoplastic or malfunctioning right
ventricle to pump the inferior vena cava
venous return into the pulmonary circula-
tion, deviating the venous return from the
superior vena cava directly into the pulmo-
nary circulation with an end-to-side anas-
tomosis to the right pulmonary artery (bi-
directional Glenn). This approach of one-
and-a-half ventricular repair, which is of
course suitable only in the presence of nor-
mal pulmonary vascular resistance, has
been proved successful in various reported
experiences.2-4
For patients in group 2, with elevated
pulmonary vascular resistance, not suitable
for a Fontan type of procedure or with
failing Fontan procedure, the authors did
not provide any proof that their technique
with the two right ventricles will allow the
heart to overcome elevated pulmonary vas-
cular resistance. They did demonstrate that
the system with two right ventricles can
work in the short term, but they did not
provide any data regarding the possibility
for this combination with an unprepared
donor right ventricle of supporting either a
right ventricular volume overload or a pres-
sure overload.
At this point, if we have a donor heart
available and wish to consider a donor ven-
tricle to pump against elevated pulmonary
vascular resistance in heterotopic position,
we consider it much better to use a donor
left ventricle. A left ventricle is definitely
able to overcome very high pulmonary vas-
cular resistance, at least up to a systemic
level.
This idea was tested in an acute exper-
imental study performed when I was at
University of California, Los Angeles, and
we were able to prove that our heterotopic
right heart assist transplant (heart with two
left ventricles) was able to function against
pulmonary vascular resistance artificially
elevated to the systemic level.5 Although
this technique requires a little more com-
plicated surgical approach and understand-
ing, as the technique reported by Elefteri-
ades and coworkers1 does not require
cardiopulmonary bypass, it could poten-
tially applied to a much larger patient pop-
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ulation, particularly including children
with severe pulmonary hypertension.
Antonio F. Corno, MD, PD, FECTS, FRCS
Service de Chirurgie Cardio-vasculaire
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
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Reply to the Editor:
We appreciate the kind comments of Dr
Corno in his letter regarding our article.1
We also appreciate his astute delineation of
the categories of congenital conditions in
which our technique could be applied clin-
ically. We wish to emphasize, however,
that ours is at this point an experimental
technique, confined to short-term applica-
tion in the experimental laboratory. We are
not advocating clinical application at this
time.
To address Dr Corno’s specific com-
ments, we need to distinguish between two
different experimental procedures devel-
oped in our laboratory, which are easily
confused because both rely on surgical sep-
aration of the right and left ventricles into
independent units. In the experiments to
which the letter is addressed, we trans-
planted an accessory donor right heart onto
a complete recipient heart, the accessory
right heart transplantation procedure. This
is being investigated as an alternative treat-
ment for congenital hypoplastic lesions of
the right side of the heart in children. In an
earlier series of experiments,2 we reported
an experimental right heart–sparing proce-
dure in which the right ventricle of a recip-
ient is preserved and a complete donor
heart is implanted. This latter procedure is
intended, in principle, for human recipients
with severe ambient pulmonary hyperten-
sion, a setting in which right heart failure,
possibly lethal, is frequently encountered.
Both these experimental operations rely on
the physical separation of right and left
sides of the heart, but they represent essen-
tially converse procedures for completely
disparate indications.
Dr Corno enumerates other operations
that may have application to patient groups
with right ventricular hypoplasia or clinical
decompensation after conventional pallia-
tive surgery. We agree that the one-and-a-
half ventricular repair about which he and
others have published has merit. This ap-
proach allows a bidirectional Glenn shunt
to perfuse the lungs with the superior vena
caval flow, while the diminutive right ven-
tricle continues to pump the inferior vena
caval flow to the pulmonary artery. We
hasten to point out that this repair uses the
native one-and-a-half ventricles and should
not be confused with our right ventricle–
sparing transplant operation,2 which has at
times been called the “heart-and-a-half”
operation.
We agree fully that the acute experi-
ments presented in our article did not sub-
ject the accessory right heart to ambient
pulmonary hypertension. In related exper-
iments currently in press,3 our converse
procedure of right ventricle–sparing trans-
plantation did successfully cope with se-
vere induced iatrogenic pulmonary hyper-
tension.
We agree that heterotopic transplanta-
tion represents a viable solution in many
situations in which pulmonary hyperten-
sion precludes traditional orthotopic car-
diac transplantation. In short-term experi-
ments, Corno and colleagues used the left
ventricle of a full heterotopic transplant to
perfuse the right-sided circulation. There
are several advantages to transplanting an
isolated right heart. The operation can be
done without cardiopulmonary bypass.
Space issues are minimized, because there
is no left ventricle. Finally, the potential
donor pool is quite large and different from
the standard donor pool, because hearts
with left ventricular dysfunction may be
acceptable. In fact, such hearts might even
be preferable, because they have “precon-
ditioned” the right ventricle against left
ventricular failure.
Standard heterotopic transplantation,
described in the early era of clinical cardiac
transplantation, continues to be quite lim-
ited in application, largely because of prob-
lems of embolization and arrhythmias orig-
inating in the preserved native left ventricle
and because of mass effects of the hetero-
topic heart in the pulmonary space. Our
right heart–sparing transplant procedure
was designed to avoid these problems.
We congratulate Dr Corno on the im-
portant work he has highlighted and thank
him for his insightful commentary on our
recent article.
John A. Elefteriades, MD
Gary S. Kopf, MD
Section of Cardiothoracic Surgery
Yale University School of Medicine
New Haven, CT 06510
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The radial artery: Neither gold, nor
silver, but bronze?
To the Editor:
I greatly appreciated reading Dr Lytle’s
insightful comments in his editorial on
the radial artery (RA) versus the right
internal thoracic artery (RITA) as a sec-
ond arterial conduit for coronary sur-
gery.1 All that he says is true: the RITA
graft, when considering its historical
older brother the left internal thoracic
artery (LITA) graft, should have the same
long-term potential but technically poses
a bigger challenge. Hence surgeons opt
for a more user-friendly arterial conduit,
the RA. I would like to suggest a differ-
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